vTv Therapeutics to Present at Stifel 2015 Healthcare Conference

HIGH POINT, N.C.--()--vTv Therapeutics Inc. (Nasdaq:VTVT), a clinical-stage biopharmaceutical company engaged in the discovery and development of new orally administered treatments for Alzheimer’s disease (AD) and diabetes, today announced that Stephen Holcombe, President and CEO, Aaron Burstein, SVP, Clinical Development, and Carmen Valcarce, SVP, Chief Scientific Officer, will be presenting a corporate and clinical overview at the Stifel 2015 Healthcare Conference. The presentation will take place at 1:30 p.m. EST on Tuesday, November 17, 2015 at The New York Palace Hotel in New York City.

A live webcast of the presentation can be accessed on the News & Events section of the website. The webcast will be archived for 30 days following the presentation on the company website at www.vtvtherapeutics.com.

About vTv Therapeutics Inc.

vTv Therapeutics Inc. is a clinical-stage biopharmaceutical company engaged in the discovery and development of orally administered small molecule drug candidates to fill significant unmet medical needs. vTv has a pipeline of clinical drug candidates led by programs for the treatment of Alzheimer’s disease and Type 2 diabetes as well as treatment of inflammatory disorders and the prevention of muscle weakness.

Contacts

Investors
The Trout Group
Josh Barer, 646-378-2948
jbarer@troutgroup.com
or
Media
BMC Communications
Brad Miles, 646-513-3125
bmiles@bmccommunications.com

vTv Therapeutics Inc.